New drug MP-424 shows promise against hepatitis c in early trial
NCT ID NCT00621296
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tested MP-424 (Telaprevir) in 15 people with genotype 1b hepatitis C who had not been treated with interferon before. Participants took three 250 mg tablets every 8 hours for 24 weeks. The main goal was to see if the virus became undetectable 24 weeks after treatment ended.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MP-424 (Telaprevir)
- What this could lead to
- If successful, this could point toward a new treatment option for hepatitis C that helps clear the virus from the body.
- What could go wrong
- This is a small, early-phase trial with only 15 participants, so results may not apply to everyone. The drug may cause side effects or fail to eliminate the virus.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Toranomon Hospital
Kawasaki, Takatsu-ku, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Finger-Prick could change the fight against hepatitis c
- A simple finger prick could transform hepatitis c care
- Can coaching clinics curb HIV? a new strategy puts it to the test
- Can hepatitis c be cured in just 4 weeks? a new trial puts it to the test
- Can a simple roadside test catch liver disease before it turns deadly?
- Pharmacy-Based hepatitis c testing could cure more people on opioid therapy